INTRODUCTION
The quest to discover or develop new medicines to facilitate healthcare management for a growing and ageing global population is a long and difficult task. Although knowledge of the human genome and the proteins encoded by it has helped to identify new drug targets, our understanding of proteins, ligands and their complexes is still relatively superficial. Proteins are the most common molecular target of drugs, since they play an essential role in cellular activity. Understanding protein-ligand interactions, whether the protein is an enzyme, transporter, ion channel, or G-protein coupled receptor (GPCR), or whether its ligand is a natural ligand, substrate or drug molecule is therefore of fundamental importance across many biological, biochemical, and biophysical disciplines.
As recognised in the late 19 th [1] and early 20 th [2, 3] centuries, in order for the effective occurrence of cellular processes and drug-mediated interventions, these processes rely upon ligand binding to the protein target to form a complex. These cellular proteins, which are the targets for drug molecules are termed receptors. The term receptors is now more commonly used for a subset of proteins that act as intracellular binding partners for chemical messengers, and for clarity within this chapter we will continue to refer to protein-ligand interactions (although these may be interchanged with terminology such as receptor-ligand, receptordrug, etc.).
The process termed molecular recognition by which the protein and ligand interact is dependent upon factors such as surface complementarity, hydrophobicity, and electrostatics. A detailed understanding of these principles at a microscopic and macroscopic level is required in order to begin to understand how to rationally design new drug molecules.
Thus, to fully understand protein-ligand interactions and to utilise this information to make an impact on drug discovery and healthcare requires that the biophysical properties of the protein, ligand and the protein-ligand complex be investigated.
OVERVIEW OF DRUG DISCOVERY
The goal of drug discovery is to utilise the knowledge of and interplay between chemistry, biology and pharmacology in order to design and develop new medicines. Understanding and modifying interactions between ligands, designed during the drug discovery process, and both target and other proteins are critically important steps that must take place in order to progress projects.
Historically, the approach to discovering drug molecules targeting proteins involved in disease mechanisms was to investigate compounds isolated from various natural sources. Overall, these compounds are involved in the treatment of many human diseases [4] . This important starting point has provided a rich source of drugs including chemotherapy agents (e.g. paclitaxel), immunosuppressive drugs (e.g. cyclosporins) and cholesterol lowering drugs (e.g. the statins). Modern drug discovery, however, utilises both the skill of the medicinal chemist to provide creative solutions to improve compound properties, along with genomics and proteomics approaches (5) to identify proteins involved in relevant biological pathways.
Target selection is achieved from a combination of the understanding of biological processes and molecular approaches aimed at identifying protein target modulation which could provide clinical benefits in the relevant disease setting [6] .
Most targets are proteins, with most drugs being small molecular compounds which interact physically with the target and alter its biological function. Biological understanding was traditionally the main target discovery strategy, and it remains important for diseases in which the relevant phenotype can only be detected at the whole body level, such as atherosclerosis, obesity, heart failure, hypertension and neurodegenerative disorders. Molecular approaches are driven by technologies that attempt to correlate molecular changes with human disease, such as changes in gene expression (genomics), protein expression (proteomics) or genetic variation. The absence or mutation of a particular gene can result in serious disease or the risk of contracting a disease, examples include the link between apolipoprotein A and cardiovascular disease, or BRCA 1 and 2 and breast and ovarian cancer. Following the selection of the protein target, several approaches are taken for hit and lead identification. These include in silico methods, combinatorial chemistry and high-throughput screening utilising the resultant corporate compound libraries. Hits are identified as those compounds showing activity in the assay. The lead identification process is designed to identify several structurally distinct chemical series that produce the desired pharmacological effects, have acceptable drug like properties or the potential for optimisation and are patentable. Another valuable source of leads is from competitor compounds, where the aim is to identify groups from those compounds, which may be modified to improve physicochemical properties, whilst avoiding competitor patent restrictions. This approach can lead to dramatic improvements in biological and pharmacokinetic profiles, and is reflected in the quote from Nobel Prize winner Sir James Black (1924 -2010): "The most fruitful basis for the discovery of a new drug is to start with an old drug".
It is during this lead optimisation stage that structure-activity relationships (SARs) are developed with respect to potency for the target protein. Selectivity considerations, detailing which other proteins the ligand may bind to, and their relative affinities, also are investigated. It is also at this stage that drug metabolism and pharmacokinetics (DMPK) investigations begin.
During lead optimisation, 2-4 compounds that meet the candidate drug target profile are identified by applying medicinal chemistry to produce analogues of a lead series [7] . It is thus here, that these lead compounds are optimised with respect to potency, selectivity, DMPK and chemistry scale up is begun.
At the same time, the clinical strategy is defined, and markers of drug action and disease effect are characterised.
Once a suitable drug candidate is found preclinical testing begins, where the aim is to evaluate safety, toxicology, metabolism and pharmacokinetics of the developed compound. This will involve in vitro, in vivo and ex vivo testing as required by the regulatory authorities.
Clinical trials are then required, but before use a drug needs to be approved by either the Food and Drug Administration (FDA) or the European Agency for the Evaluation of medicinal Products (EMEA). During the first part of these trials, the candidate drug is administered to healthy volunteers (Phase I), in order to assess drug safety, possible side effects and to gather basic pharmacokinetic information. During the next stage (Phase II), the drug is given to patients with the disorder for which the candidate drug is a proposed treatment. It is here that the dosage will be evaluated and preliminary data on efficacy in patients collected. Subsequently, the drug will be given to a larger number of patients (Phase III), allowing the drug to be compared to existing therapies and enabling statistics to be collected on any adverse reactions [8] .
PROTEIN-LIGAND BINDING EQUILIBRIA, THERMODYNAMICS AND KINETICS
Assuming that the protein, P, has a single binding site for the ligand, L, and the binding interaction is a reversible bimolecular reaction: We also can then describe the change in Gibbs free energy (G) for the binding reaction by the equation:
where G° is the standard free energy change, R is the gas constant (8.31 J mol -1 K -1 ), and T is the temperature in Kelvin. At equilibrium, where G = 0, then the equation becomes:
If we represent the ratio of the reactants and product concentrations as the equilibrium dissociation constant
, then we obtain:
The equilibrium dissociation constant is most often used in biochemical studies because it has units of molarity, and so may be related to the ligand concentration leading to half maximal saturation of the protein. It describes the strength of the interaction between protein and ligand, with lower values representing tighter binding.
Because the G° may be described by the change in standard enthalpy (H°) and standard entropy (S°), these parameters can also be related to K d :
The enthalpy represents the energy reduced by so called volume work of a reaction at constant pressure, and the entropy represents the degree of disorder introduced by the energy being distributed over the number of accessible degrees of freedom. We can see that for a spontaneous binding interaction, where G° is negative, that a decrease in enthalpy and an increase in entropy are favourable contributions to an increase in binding affinity.
Thus, it can be seen that the equilibrium dissociation constant is derived from thermodynamic principles and can be related to fundamental thermodynamic parameters. A K d value of 1 nM, which is a value commonly observed for optimised leads or even candidate drugs, corresponds to a Gibbs free energy of binding of -53.4 kJ mol -1 at body temperature, with a ten fold change in affinity representing a change of 5.9 kJ mol -1 The binding interaction may also be described in kinetic terms, because the equilibrium between free partners and the protein-ligand complex will be governed by the rate of complex formation and rate of its dissociation. The second order rate constant for association is termed k on , and the first order rate constant for dissociation is k off , as shown above.
The K d is given by the ratio of the rate constants:
For diffusion controlled binding, where the association rate constant (at least for enzyme-substrate interactions) can be up to 10 9 M -1 s -1 [9] -10 10 M -1 s -1 [10] , while the dissociation rate constant for a K d value of 1 nM will be 1 -10 s -1 .
In the situation where a large excess of ligand is required to produce a significant degree of binding to the protein, then binding occurs with little change in the free ligand concentration, and so the association reaction occurs with pseudo-first order kinetics, so that:
where [PL] t is the concentration of the protein-ligand complex at time t, [PL] eq is the concentration of the complex at equilibrium and k obs is the pseudo-first order rate constant.
The value of k obs for a reversible interaction is given by:
Hence, a plot of k obs versus [L] f will allow the rate constants and hence the K d to be evaluated.
For this single step reversible equilibrium the residence time,, (the length of time the ligand occupies the protein binding site) is given by 1/k off .
Although it is possible to determine the K d value from kinetic measurements, as shown above, these values can often be difficult to measure, because they occur on a short timescale, and so K d values are often measured at equilibrium.
Many protein-inhibitor binding interactions of importance in drug discovery proceed more slowly than the diffusion controlled limit, and often exhibit slow binding inhibition.
This typically occurs via a two step mechanism,
where the enzyme encounters the ligand and subsequently a tightening of the initial interaction occurs, for example via a conformational change, allowing a tighter binding steady state complex PL* to form.
This situation is described by two dissociation (or, more correctly, inhibition) constants, K i and K i *.
The second inhibition constant is given by:
For this type of interaction the k obs is given by a more complicated combination of rate constants:
where K i ' is the apparent K i which will depend upon the mechanism of inhibition and the substrate concentration, and may be related to the true K i value according to the Cheng-Prusoff equation [11] :
where K is and K ii are the inhibition constants at
The residence time for the two step binding mechanism is given by:
Two step mechanisms such as this appear to be common in drug discovery, with many inhibitors displaying slow kinetics according to this mechanism. The second step is slow which is often attributed to conformational rearrangements or even irreversible inhibition such as in the case where k 2 or k 4 tend to zero.
Investigation into the kinetics and thermodynamics of the binding interaction is an invaluable tool in drug discovery as it may help to identify compounds which act by preferred or alternative mechanisms.
NON-COVALENT INTERACTIONS IN PROTEIN-LIGAND BINDING
Molecules can interact with each other via a number of non-covalent interactions that are mediated by surface complemenatrity between the protein binding site and the ligand. These weak attractive forces are important in molecular recognition occurring in biochemical binding reactions because they occur reversibly.
As these interactions are weak in nature, multiple interactions are usually required for the formation of a stable binding complex, and the interacting groups tend to be in close proximity.
The four types of non-covalent interactions important in protein-ligand binding are hydrogen bonding, ionic or electrostatic interactions, van der Waals forces and hydrophobic interactions.
Hydrogen bonding
Hydrogen bonds are electrostatic attractions between two dipoles and form when a hydrogen atom is shared by two electronegative atoms, referred to as the donor (to which the hydrogen is covalently bonded), and the acceptor. In proteins the electronegative heteroatoms are predominantly oxygen or nitrogen.
Hydrogen bonds are weak, contributing around 12.5 -21 kJ mol -1 , with the actual strength being dependent upon several factors including the local medium, but in particular the distance and direction between the hydrogen and the acceptor [12] .
Although individually weak, hydrogen bonding is the largest contributor to the binding energy of ligands, as well as to the structural elements within a protein structure.
Ionic or electrostatic interactions
These interactions occur when two oppositely charged groups are attracted to one another through a Coloumbic force. It has been suggested that these interactions are likely to be responsible for the initial recognition of protein and ligand.
The strength of the interaction is dependent upon the charges on the two atoms, as well as the distance between them and the dielectric constant of the medium.
Many ligands rely on ionic interactions for specific binding, with the greatest attractive force occurring in the low dielectric constant environment of the hydrophobic interior of the protein.
Van der Waals interactions
Van der Waals interactions occur as a result of the attraction between temporary dipoles that arise due to the uneven distribution of electrons between neighbouring atoms. This attractive force is much weaker than ionic or hydrogen bonds, with an energy of no more than around 4 kJ mol -1 . However, due to high surface complementarity between protein and ligand, the number of van der Waals interactions can be large, with the collective force contributing significantly to complex stability.
Hydrophobic interactions
Hydrophobic interactions occur between two non-polar groups, due to the reduction in the unfavourable organisation of water around the non-polar groups, when the groups associate with one another [13] .
For ligand binding, the hydrophobic region of the binding site tends to stabilise the binding of hydrophobic ligands. This hydrophobic portioning of ligands from solution to the protein active site can be a strong contributor to the binding energy.
BIOPHYSICAL METHODS FOR CHARACTERISING PROTEIN-LIGAND INTERACTIONS

Isothermal titration calorimetry (ITC)
The ITC experiment involves the monitoring of the heat change during the binding reaction (for a comprehensive protocol see [14] ). The ligand solution is usually titrated from the injection syringe into the protein solution contained within the calorimeter cell. The instrument measures the heat change using a power compensation process whereby the difference in the variable power, proportional to the binding heat, applied to the sample cell and the constant power applied to the thermal reference cell is monitored by the instrument.
Depending upon the binding affinity and the amounts of available reagents, it is often possible to arrange the experimental conditions so that a single experiment can provide precise estimates of the affinity (K d ), the enthalpy (H) and the stoichiometry (n) of the binding interaction. This also allows calculation of the entropy (S) from the Gibbs-Helmholtz equation, above.
During the titration, in which small aliquots of the ligand solution are added, the first injections generate the largest heat change as most of the added ligand becomes bound to the protein. As the titration progresses the protein becomes increasingly saturated with ligand, and the heat differential heat change becomes smaller. Finally, following complete saturation, no further heat change is detected. However, sometimes significant, non-zero heats following saturation are observed, which are often attributable to the heat associated with dilution of the ligand, and can be corrected for by control titrations. Understanding the thermodynamic components of molecular interaction is important in drug discovery, as it allows optimisation of test compounds in a more meaningful way. The thermodynamic measurements that are made accessible through the ITC experiment are fundamental in trying to understand molecular interaction, and in applying that learning in the pursuit of compounds, not only with higher affinity, but with the appropriate thermodynamic and kinetic profiles for their biological function [15] .
As shown above, the binding affinity of a test compound is related to the free energy of the interaction, which itself is dependent upon the enthalpic and entropic components. The situation is complicated by factors such as the influence of solvent water on the binding thermodynamics and the change in dynamics and conformation of the ligand and protein between the free and bound states. This makes the individual thermodynamic parameters incredibly difficult to predict.
Because ITC allows measurement of affinity and enthalpy in a single experiment, it can be useful in determining discontinuities in SAR which may be missed from K d values alone. Changes in enthalpy may provide a valuable approach for the selection of compounds during lead identification and in helping to guide the lead optimisation process towards compounds of higher quality. Enthalpic optimisation, where the enthalpy of interaction is increased moving from early to later marketed drugs, has been suggested as a useful approach to obtain advantages in the clinic [16, 17] . The approach suggests that more efficient optimisation can be achieved if the contributions of both enthalpy and entropy are improved simultaneously [18] .
By proactively using ITC to help guide medicinal chemistry in this way, we will inevitably initiate the exploration of the relationship between thermodynamics and structure in a more coherent manner that will enable us to increase and exploit our knowledge of molecular interaction.
Surface Plasmon Resonance (SPR)
Optical biosensors measure changes in some characteristic of light, coupled to changes (often in mass) at the sensor surface by making use of the electromagnetic evanescent-wave formed at the gold interface of the sensor chip surface. Biosensors employing SPR, such as BIAcore (GE Healthcare), are the best-known optical biosensors, utilising this phenomenon to enable detection of protein-ligand interactions in real time.
At total internal reflection, the electromagnetic field component of the incident light (the so-called evanescent wave) penetrates into the gold film on the sensor chip and interacts with free electrons or plasmons. Photons of incident light are absorbed, the evanescent field strength amplified, and the light is no longer reflected. This decrease in the reflected intensity occurs at an angle which depends on the refractive index of the material in the flow cell, and is called the SPR angle. The refractive index of the flow cell changes concomitantly with mass on the surface and thus allows detection of ligand binding events, Figure 4 .2 (for a review of the use of SPR in drug discovery see [19] ). This potentially allows the kinetic and equilibrium constants for a given interaction to be determined. In order to monitor protein-ligand binding, one of the partners has to be immobilised onto the sensor surface. In direct binding assays (DBA) the target protein is coupled, without compromising the activity or functionality of the protein or the accessibility to the binding site. Several different methods are available in order to achieve this, with the most common being direct immobilisation via accessible primary amines exposed on the protein surface. This is achieved by activating the carboxymethyl-dextran matrix surface with a mixture of 1-ethyl -3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) to introduce reactive succinimide esters that can react spontaneously with protein primary amines. Other immobilisation methods are available employing either covalent attachment using different chemistry strategies, or by employing non-covalent capture using affinity methods, employing tags specifically incorporated within the protein.
The SPR signal is dependent on several factors associated with the target protein, including the molecular weight (MW) of the attached protein, the amount captured on the surface and the binding capacity of the protein, or the stoichiometry of the binding reaction. Factors associated with the ligand are also the MW, the total concentration, [L] t and the equilibrium dissociation K d . The dependence upon MW and K d for the small molecule ligand represents a particular challenge when working with fragments, where both size and affinity are low.
Issues that arise due to ligand molecular size may be circumvented by the use of alternative assay formats such as the surface competition assay (SCA) or inhibition in solution assay (ISA). The ISA overcomes these issues by monitoring binding of the macromolecule, whereby increasing test compound concentration results in a decrease in observed signal as the test compound competes for binding to the target protein, and thus makes systems amenable for small molecule work that may be out of the scope of direct binding.
The ISA format requires coupling of a tool compound, or so called target definition compound (TDC), to the biosensor surface which then serves as a probe for the binding site. The binding interaction between the TDC and the protein generates a control signal which will be lowered in the presence of competing test compounds. Only compounds showing kinetic competition with the TDC for binding to the target protein will reduce the amount of free protein available at equilibrium to bind to the TDC. This approach thus allows affinity information for the test compound to be derived [20] .
An essential part of the initial development of an ISA is the identification of a suitable tool compound to be used as a TDC. Ideal properties for a suitable TDC would be binding which blocks the whole binding site, with rapid association kinetics and high potency (slow dissociation). This situation serves to ensure mass transport limited kinetics, so that the observed signal is proportional to the concentration of free target protein, with the biosensor essentially measuring the free protein concentration resulting from incubation with different concentrations of test compound. Attachment of the TDC via primary amines without compromising binding to the target protein is also the preferred attachment approach.
In addition to an absence of MW-limitations for proteins or ligands in the ISA, another major advantage is that the interaction of interest occurs in solution, alleviating any issues with potential changes in affinity caused by immobilisation. The protocols for immobilisation and regeneration are usually straightforward, as conditions usually too harsh to be used with immobilised protein can be routinely used with the small molecule attached to the surface. However, the main disadvantage compared to the DBA is that determination of the kinetic parameters is precluded by the ISA method.
Optical waveguide grating (OWG)
Biosensor instruments using optical waveguide-based systems have been growing in use recently. Both Corning and SRU Biosystems, manufacture instruments (EPIC and BIND, respectively) that allow increased sample throughput by using plate-based platforms.
These instruments make use of the evanescent waves formed when light travelling through a boundary between two media of different refractive indices undergoes total internal reflection. Wave coupling is then achieved by placing electromagnetic elements, such as optical waveguides, close together enabling propagation of a wave from one element to the next. Changes in the refractive index at the interface between the sensor surface and the solution phase, occurring as a consequence of ligand binding, modifies the wave coupling and triggers a change in the reflected or transmitted light. This allows changes in mass at the sensor surface, caused by binding to proteins attached to sensor surface, to be monitored (for a review of waveguide-based biosensors see [21] ).
The main practical difference between the EPIC and BIND OWG systems to SPRbased systems is the absence of solution flow. Thus, the OWG systems are unable to measure accurate kinetics. However, this apparent disadvantage is compensated for by (1) increased throughput and (2) the ability to add several components either simultaneously or sequentially into the same well of the plate in order to study the effect of addition.
As with SPR-based platforms, ISA formats can be useful on OWG platforms. Many of the limitations described above for SPR are also problematic for OWG platforms. Limitations in sensitivity for small molecule binding represent a major challenge. Often, to overcome these issues, proteins are coupled at high density, resulting in high local concentrations. This leads to an increased risk of nonspecific binding due to the potential increase in aggregated, unfolded, or functionally compromised proteins coupled to the sensor surface.
Thus, the immobilisation of a tool compound or TDC and making use of the ISA approach will circumvent these issues.
The use of these technologies is expected to expand as issues with protein immobilisation are overcome, perhaps via expansion of the available immobilisation chemistries and/or the sensitivity of detection improves.
Spectroscopic methods -Nuclear Magnetic Resonance (NMR)
Following the introduction of SAR by NMR by Fesik in 1996 [22] , NMR has been an important tool for detecting protein-ligand binding in the lead generation phase of drug discovery. In fact, this ligand screening application has now almost completely replaced the use of NMR for structure solutions, which is predominantly achieved using X-ray crystallography.
Protein-ligand interactions for most soluble target proteins can be studied by NMR, and the assays are simple and robust generating few false negatives or false positives. [23] , to provide a fingerprint of amide or methyl groups in the protein, respectively. Specific changes in individual residues are then monitored upon the addition of binding ligands. Residue peak assignments also can be obtained through a series of additional 3D NMR experiments, allowing analysis of the binding mode.
The approach has a wide dynamic range, identifying binders from mM to nM range, but quantitative K d measurements are most reliable in the low affinity (μM to mM) range, under fast ligand exchange. Non-specific binding is generally not problematic in 2D NMR experiments since such binders are either not detected or tend to produce non-specific line broadening.
The requirement for an isotopically labelled protein and the size restriction up to around 40 kDa (80 kDa if uniform deuteration of the protein can be achieved) places some limitation on the application of 2D NMR.
1D NMR direct binding and reference displacement
In 1D NMR ligand signals are observed directly. This can be advantageous in offering a built-in quality control and solubility measures for the test compounds studied. There is no limit on protein size, with larger proteins giving increased relaxation effects, resulting in magnified ligand binding effects. Generally, 1 H detection is used for 1D ligand-observe NMR, with the most common techniques being waterLOGSY, saturation transfer difference (STD), and T1ρ and T2 filtered experiments [24, 25] .
1D NMR screening can be run either in direct binding mode where ligand binding is observed directly, or by monitoring the competition with an established reference ligand, often termed a spy molecule or reporter ligand.
The direct binding method is extremely sensitive, with binding effects observed even at ligand concentrations well below K d, although competition with a ligand that is known to bind to the site of interest is required to ensure that the binding interaction is specific.
A major limitation of the 1D NMR direct binding approach is that the magnitude of the binding effect decreases when the binding approaches high affinity (nM) or there is a slow ligand exchange regime, although this is not problematic for the competition method.
Typically, NMR approaches use compound mixtures, in order to increase the throughput of the techniques. Mixtures can be screened in direct 1D NMR without subsequent deconvolution, if reference spectra for the ligands in the mixture have been previously measured. Reference displacement methods require deconvolution to identify hits present in the mixture. Thus, typical screens comprising up to several thousand compounds are often completed in a timescale covering a few days to several weeks depending upon the screening mode.
Spectrometric methods -Mass Spectrometry (MS)
MS approaches for assessing protein-ligand binding may be grouped into 2 main types: (1) direct detection of the ligand and (2) detection of the protein-ligand complex.
Direct detection of the ligand
MS analysis of small molecules is a routine technology. Its strength is that hits can be identified by mass, allowing mixtures of compounds (with different MW) to be utilised during study. This, however, requires the separation of binders from nonbinding compounds directly before the MS analysis step. This separation of bound from unbound compounds can be achieved in a variety of ways including size exclusion chromatography, ultrafiltration, equilibrium dialysis, or frontal affinity chromatography. These approaches are suited to liquid chromatography electrospray ionisation MS (LC-ESI-MS) which facilitates protein denaturation and the release of the bound ligand.
For size exclusion based separations, the target protein is incubated with one or a mixture of potential ligands before chromatography. The chromatographic step rapidly separates unbound compounds from those bound to the protein before analysis by LC-ESI-MS. This approach is amenable to high throughput screening (HTS).
Using the ultrafiltration approach, the target protein is incubated with potential ligands before being concentrated in a centrifugal device with a semi-permeable membrane. Unbound compounds pass through the membrane and become significantly diluted, beyond MS detection limits. Bound ligands are retained in the protein-containing sample, and are identified by LC-ESI-MS.
In equilibrium dialysis (ED) compound mixtures are allowed to fully equilibrate between two chambers separated by a membrane permeable to only the compounds, with one chamber containing the target protein. The contents of the two chambers are analyzed quantitatively by LC-ESI-MS; with bound ligands identified as the total concentration in the protein-containing chamber will be higher than that on the protein free side [26] .
A fundamentally different approach is frontal affinity chromatography, in which the target protein is immobilized onto a liquid chromatography column. Com-pounds are introduced and detected after the column step by ESI-MS. Changes in retention volume, indicating binding, allows bound ligands to be identified [27] . With the introduction of tool ligands with known affinity, competition experiments can be performed to estimate binding affinity for test compounds.
Detection of the protein-ligand complex
Native mass spectrometry [28] has been shown to identify non-covalent proteinligand complexes, as the conditions allow the protein to retain a native fold and retain bound ligands in the gas phase [29] . This screening approach has been employed for standard libraries [30] and also has been used for screening fragments [31] .
BRIEF CASE STUDIES EXEMPLIFYING THE USE OF BIOPHYSICAL METHODS
The most powerful use of biophysical methods is in the combination of approaches, either across the biophysical methodology range, or coupled with biochemical data aimed at addressing specific problems during the drug discovery process. The examples below refer to drug discovery projects carried out at AstraZeneca, where the use of biophysical methods was integral to project progression.
DNA gyrase
DNA gyrase is a bacterial topoisomerase, essential for DNA replication and cell viability. Topoisomerases are the only DNA replication targets validated by drugs in the clinical setting, and DNA gyrase is well conserved across all bacterial pathogens of interest.
The DNA gyrase enzyme relieves the supercoiling of DNA generated during replication and transcription, and uses the energy from ATP to catalyse the DNA topology changes. It is a tetrameric enzyme composed of a dimer of dimers, with the A subunits involved with DNA cleavage and resealing and the B subunit (GyrB) responsible for the ATPase activity.
24 kDa and 43 kDa fragments of the DNA gyrase B subunit were used for structural biology efforts and with both ITC and NMR methods in order to help identify and characterise gyrase binding compounds. ITC was used to investigate the binding affinity and thermodynamics of compounds binding to these protein fragments. The utility of the ITC method can be emphasised in this project, as these fragments of the B subunit lack the topoisomerase-linked ATPase activity of the intact tetramer, and so traditional biochemical methods following catalytic activity could not be used to measure test compound affinity.
In a subsequent fragment based approach, 2D NMR was used to screen a library of low molecular weight fragment compounds containing both generic fragments and fragments of known gyrase inhibitors. The 2D NMR method allowed both affinity and binding site information to be obtained. The fragment hits were found to have high ligand efficiency (G/ heavy atom) of up to 0.46, and shared a hydrogen bond donor/acceptor motif similar to the adenine moiety of ATP.
Having identified a naphthol fragment as an efficient binder to the primary fragment site, a secondary screen was undertaken using the GyrB:naphthol complex. Following identification of a weak (5 mM) binding quinoline, docking methods suggested likely orientations of the 2 fragments and allowed a linking strategy to be followed to improve potency, Figure 4 .3a.
(a) (b) Improved potency was driven by optimisation of the GyrB interactions, making substitutions on a pyrrole moiety to fill site 1. Additional hydrogen bonding interactions were incorporated into site 2, which extended into the novobiocin binding pocket, whilst maintaining the ligand efficiency at 0.39, Figure 4 .3b.
The pyrrolamide series [32] of established compounds maintain potency against a range of drug resistant bacterial strains, are bactericidal with low resistance frequency and demonstrate potency against a broad spectrum of bacteria.
Beta-site APP cleaving enzyme 1 (BACE-1)
Combinations of NMR and SPR methods have been applied in the search for inhibitors of BACE-1.
BACE-1, also known as beta-secretase 1, is an aspartic acid protease which cleaves amyloid precursor protein (APP) extracellularly. This cleavage step is a prerequisite for the subsequent cleavage by gamma-secretase to the 40 or 42 amino acid amyloid  peptides. The aggregation of these peptides in the brain leads to Alzheimer's disease. 1D NMR screening was undertaken with BACE-1 protein expressed as a C-terminal fusion of the Fc part of human IgG1. Due to the large size of this fusion protein, which causes increased relaxation effects, enhanced ligand binding effects occur and low micromolar concentrations of protein could be used to carry out the screening. A fragment library of 2000 generic fragments was screened using waterLOGSY competition experiments. The fragment library was screened in compound mixtures containing 6 compounds, and resulted in a hit rate of around 0.5 %. Following the initial fragment screen, an inhibition in solution assay was established on the BIAcore platform, using a TDC peptide. The P1 (S)-statin substituted substrate analogue (KTEEISEVNstatin-DAEF) was captured using amine coupling, and displays nM affinity to BACE-1. A reference surface was also prepared with a scrambled version of the peptide (KFES-statin-ETIA-EVENV). Initial binding of the fragment hits from the NMR screen were tested at 1 mM, with subsequent concentration responses carried out over the 0.1 -5 mM range. This fragment based NMR screening approach coupled with BIAcore follow up confirmation and analogue testing resulted in the identification of a range of 6-substituted isocytosines as novel warheads for BACE-1 inhibition, with ligand efficiencies of around 0.3, that were subsequently developed into inhibitors with nanomolar potency and cellular activity, Figure 4 .4 [33] . , and showed that the MEK-1 inhibitor U-0126 demonstrates noncompetitive kinetics, whereas an alkyl amide compound showed uncompetitive kinetics. This work illustrates that the determination of the mechanism of action and measurement of equilibrium dissociation and inhibition constants helps in the understanding of the structure-activity relationships of MEK inhibitors [34] .
FUTURE TRENDS FOR BIOPHYSICAL APPROACHES
The future use of biophysical methods to characterise protein-ligand interactions will undoubtedly be facilitated by improvements in 2 key areas: (1) increased throughput and/or sensitivity of current instrumentation and (2) increased application to currently intractable targets by emerging target preparation methods or new emerging technology, or both.
Successful improvements in throughput have been exemplified over the last 20 years or so by the transformation of SPR from a single molecule characterisation tool to a method capable of driving fragment based lead generation projects, where thousands of potential ligands are tested in a single screen.
The throughput of OWG instruments has also progressed from early instruments to 384-well plate based (EPIC) and even 1536-well plates (BIND), and the Advion nanomate holds a 96 or 384 rack of conductive tips as well as a 96 or 384-well sample plate, allowing high throughput MS.
These methods will be increasingly used as orthogonal methods to verify the validity of hits derived from traditional HTS.
The possibility of increased throughput for these biophysical technologies to 1536-well based may be technically feasible, allowing an even greater impact on drug discovery in the future.
Recent efforts in building enthalpy arrays offer the potential to apply thermodynamic profiling to both a wider number and range of protein-ligand interactions and systems [35] . These instruments are arrays of nanocalorimeters that enable label-free detection of molecular interactions using small sample volumes and short measurement times compared to traditional instruments.
In terms of a newly emerging technology, an approach that has gained in interest recently is back-scattering interferometry (BSI), which is able to provide a labelfree, homogenous and mass-independent detection of ligand binding in solution with much lower requirements on sample quantity and purity than OWG and SPR methods [36] . BSI uses light interaction with a microfluidic channel to measure temporal changes in refractive index (RI), brought about upon ligand binding. Studies of unlabeled proteins with test compounds can be carried out, both in solution and following target immobilisation to the surface. Laser illumination of the microfluidic channel produces a highly modulated fringe pattern perpendicular to the channel. The bright and dark features shift position with changes in the RI of the sample and monitoring this shift forms the basis of the BSI measurement.
New technology such as this, alongside novel methods to prepare stabilised membrane proteins, such as GPCRs, using a small number of point mutations, for example the STaR technology from Heptares [37] will allow the application of biophysical methods to membrane protein systems that have been difficult to tackle previously.
Extending measurements to whole cells is also something that has been beginning to occur, particularly with OWG instruments, owing to the ability of the instrument to detect the dynamic mass redistribution that occurs with changes in cell morphology upon addition of active ligands.
The use of in-cell NMR makes it possible to study biological macromolecules while they remain in living cells. The first in-cell protein NMR experiments were performed in yeast by labelling with 19 F, although in-cell 15 N-NMR and 13 C-NMR experiments have since been conducted in Escherichia coli [38] .
The future for in-cell NMR will be the routine application of these methods to eukaryotic cells with the highly desirable opportunity to study large protein complexes and membranes.
SUMMARY
Detecting, characterising and modifying ligand binding interactions is of fundamental importance to drug discovery. Recently, a wider range of lead generation approaches, employed alongside traditional HTS, have been adopted by the pharmaceutical industry. The most important of these methods have been the biophysical techniques used either as frontline screening methods, especially in relation to fragment based lead generation, or as orthogonal methods to validate hits from high throughput or high concentration screens.
These biophysical approaches include techniques operating via a number of different physical processes that together offer the possibility of measuring not only affinity, but also the thermodynamic and kinetic contributions to that observed affinity.
This powerful combination of kinetic and thermodynamic data, coupled with structural information, allows a more detailed understanding of the binding interaction and facilitates decision making during the hit to lead and lead optimisation processes.
Further refinement, both in terms of new methodology that will allow the study of systems currently not amenable to biophysical methods and in the application of increased throughput or increased sensitivity extensions to existing methods, or both, will ensure that biophysical methods will remain embedded in high quality lead generation programmes for the foreseeable future.
